Neuraxpharm Arzneimittel GmbH

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Neuraxpharm Arzneimittel GmbH - overview

Established

1985

Location

Langenfeld, -, Germany

Primary Industry

Pharmaceuticals

About

Founded in 1985 and based in Langenfeld, Germany, Neuraxpharm Arzneimittel GmbH manufacturs generic medicines for the treatment of disroders of the central nervous system (CNS). In September 2020, Permira agreed to acquire a controlling stake in Neuraxpharm Holdco Iberia S. L. U.


for EUR 1. 6 billion, including debt.


Primary Industry

Pharmaceuticals

Sub Industries

Mental Health Services, Pharmaceutical Research & Development

Verticals

Manufacturing

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Neuraxpharm Arzneimittel GmbH - financials

Fiscal Year EndedDec 31, 2016Dec 31, 2017Dec 31, 2018Dec 31, 2019Dec 31, 2020
Revenue (USD)-104,488,046---
% Revenue Growth (YoY)-----
EBITDA (USD)-34,208,828.2---
Operating Income (USD)-3,161,128---
Operating Margin-3.0%---
% EBITDA Margin-32.7%---
NET Income (USD)(17,892,500.1)(10,638,376.9)---
% Net Margin-(10.2%)---

Neuraxpharm Arzneimittel GmbH - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Secondary BuyoutCompletedNeuraxpharm Holdco Iberia S.L.U.-
Company FormationCompletedNeuraxpharm Holdco Iberia S.L.U.-
Add-onCompletedNeuraxpharm Arzneimittel GmbH-

Displaying 1 - 3 of 3

Neuraxpharm Arzneimittel GmbH - employee data

Blurred Background

Want to see Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.